Leveraging Machine Learning for Antibody Developability Assessment
Machine learning (ML) techniques are increasingly employed in antibody drug discovery to predict developability parameters such as solubility, stability, aggregation propensity, and immunogenicity. This innovation is transforming the Antibody Drug Discovery Market by streamlining candidate selection and reducing late-stage failures.
ML models trained on large datasets can forecast problematic biophysical traits early in development, guiding the engineering of antibodies with favorable drug-like properties. This predictive capability helps prioritize candidates with higher chances of success in clinical trials.
By integrating ML into the discovery pipeline, companies can enhance efficiency, lower costs, and accelerate timelines. Ongoing advancements in computational power and data availability continue to improve the accuracy and utility of developability predictions.